This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pies, R. Search for Related Content Social Bookmarking                         What's this?

The Age of Atypical Antipsychotics

Atypical antipsychotics (AAPs) have led to refinements in the pharmacological management of schizophrenia and related disorders. Most AAPs produce fewer extra- pyramidal side effects than conventional agents, and appear to ameliorate "negative symptoms" to a greater degree. In general, many AAPs have a higher ratio of 5HT2 to D2 receptor occupancy than do conventional neuroleptics. This ratio may confer some of the "atypical" qualities to these agents, though regional brain selectivity may also be involved. Although clozapine and risperidone are the two AAPs clinicians now have available, many other similar agents are close to clinical development. Copyright © 1996 by W.B. Saunders Company

Journal of Pharmacy Practice, Vol. 9, No. 2, 113-117 (1996)
DOI: 10.1177/089719009600900207


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?